Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases

Kathleen S. Montine; Joseph F. Quinn; Jing Zhang; Joshua P. Fessel; L. Jackson Roberts; Jason D. Morrow; Thomas J. Montine

doi:10.1016/j.chemphyslip.2003.10.010

Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases

Kathleen S. Montine, Joseph F. Quinn, Jing Zhang, Joshua P. Fessel, L. Jackson Roberts, Jason D. Morrow, Thomas J. Montine

Research output: Contribution to journal › Review article › peer-review

220 Scopus citations

Abstract

Lipid peroxidation is a major outcome of free radical-mediated injury to brain, where it directly damages membranes and generates a number of oxidized products. Some of the chemically and metabolically stable oxidation products are useful in vivo biomarkers of lipid peroxidation. These include the isoprostanes (IsoPs) and isofurans (IsoFs), derived from arachidonic acid (AA), and neuroprostanes (NeuroPs), derived from docosahexaenoic acid (DHA). We have shown increased levels of IsoPs, NeuroPs, and IsoFs in diseased regions of brain from patients who died from advanced Alzheimer's disease (AD) or Parkinson's disease (PD). Increased cerebrospinal fluid (CSF) levels of IsoPs are present in patients with AD or Huntington's disease (HD) early in the course of their illness, and CSF IsoPs may improve the laboratory diagnostic accuracy for AD. In contrast, quantification of IsoPs in plasma and urine of AD patients has yielded inconsistent results. These results indicate that brain lipid peroxidation is a potential therapeutic target early in the course of AD and HD, that CSF IsoPs may aid in the assessment of anti-oxidant experimental therapeutics and laboratory diagnosis of AD.

Original language	English (US)
Pages (from-to)	117-124
Number of pages	8
Journal	Chemistry and Physics of Lipids
Volume	128
Issue number	1-2
DOIs	https://doi.org/10.1016/j.chemphyslip.2003.10.010
State	Published - Mar 2004
Externally published	Yes

Keywords

Alzheimer
Huntington
Isofurans
Isoprostanes
Neuroprostanes
Parkinson

ASJC Scopus subject areas

Biochemistry
Molecular Biology
Organic Chemistry
Cell Biology

Access to Document

10.1016/j.chemphyslip.2003.10.010

Cite this

@article{4a460b8d1d0f480ba6c9ba12488a9c66,

title = "Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases",

abstract = "Lipid peroxidation is a major outcome of free radical-mediated injury to brain, where it directly damages membranes and generates a number of oxidized products. Some of the chemically and metabolically stable oxidation products are useful in vivo biomarkers of lipid peroxidation. These include the isoprostanes (IsoPs) and isofurans (IsoFs), derived from arachidonic acid (AA), and neuroprostanes (NeuroPs), derived from docosahexaenoic acid (DHA). We have shown increased levels of IsoPs, NeuroPs, and IsoFs in diseased regions of brain from patients who died from advanced Alzheimer's disease (AD) or Parkinson's disease (PD). Increased cerebrospinal fluid (CSF) levels of IsoPs are present in patients with AD or Huntington's disease (HD) early in the course of their illness, and CSF IsoPs may improve the laboratory diagnostic accuracy for AD. In contrast, quantification of IsoPs in plasma and urine of AD patients has yielded inconsistent results. These results indicate that brain lipid peroxidation is a potential therapeutic target early in the course of AD and HD, that CSF IsoPs may aid in the assessment of anti-oxidant experimental therapeutics and laboratory diagnosis of AD.",

keywords = "Alzheimer, Huntington, Isofurans, Isoprostanes, Neuroprostanes, Parkinson",

author = "Montine, {Kathleen S.} and Quinn, {Joseph F.} and Jing Zhang and Fessel, {Joshua P.} and Roberts, {L. Jackson} and Morrow, {Jason D.} and Montine, {Thomas J.}",

note = "Funding Information: This work was supported by the Nancy and Ellsworth Alvord Endowment (T.J.M.), the Cheng-Mei Shaw Endowment (J.Z.), grants from the NIH (AG00774, AG16835, AG05114, ES10196, GM15431, DK26657, and CA77839), and a Bourroughs Welcome Fund Clinical Scientist Award in Translational Research (J.D.M.). ",

year = "2004",

month = mar,

doi = "10.1016/j.chemphyslip.2003.10.010",

language = "English (US)",

volume = "128",

pages = "117--124",

journal = "Chemistry and Physics of Lipids",

issn = "0009-3084",

publisher = "Elsevier Ireland Ltd",

number = "1-2",

}

TY - JOUR

T1 - Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases

AU - Montine, Kathleen S.

AU - Quinn, Joseph F.

AU - Zhang, Jing

AU - Fessel, Joshua P.

AU - Roberts, L. Jackson

AU - Morrow, Jason D.

AU - Montine, Thomas J.

N1 - Funding Information: This work was supported by the Nancy and Ellsworth Alvord Endowment (T.J.M.), the Cheng-Mei Shaw Endowment (J.Z.), grants from the NIH (AG00774, AG16835, AG05114, ES10196, GM15431, DK26657, and CA77839), and a Bourroughs Welcome Fund Clinical Scientist Award in Translational Research (J.D.M.).

PY - 2004/3

Y1 - 2004/3

N2 - Lipid peroxidation is a major outcome of free radical-mediated injury to brain, where it directly damages membranes and generates a number of oxidized products. Some of the chemically and metabolically stable oxidation products are useful in vivo biomarkers of lipid peroxidation. These include the isoprostanes (IsoPs) and isofurans (IsoFs), derived from arachidonic acid (AA), and neuroprostanes (NeuroPs), derived from docosahexaenoic acid (DHA). We have shown increased levels of IsoPs, NeuroPs, and IsoFs in diseased regions of brain from patients who died from advanced Alzheimer's disease (AD) or Parkinson's disease (PD). Increased cerebrospinal fluid (CSF) levels of IsoPs are present in patients with AD or Huntington's disease (HD) early in the course of their illness, and CSF IsoPs may improve the laboratory diagnostic accuracy for AD. In contrast, quantification of IsoPs in plasma and urine of AD patients has yielded inconsistent results. These results indicate that brain lipid peroxidation is a potential therapeutic target early in the course of AD and HD, that CSF IsoPs may aid in the assessment of anti-oxidant experimental therapeutics and laboratory diagnosis of AD.

AB - Lipid peroxidation is a major outcome of free radical-mediated injury to brain, where it directly damages membranes and generates a number of oxidized products. Some of the chemically and metabolically stable oxidation products are useful in vivo biomarkers of lipid peroxidation. These include the isoprostanes (IsoPs) and isofurans (IsoFs), derived from arachidonic acid (AA), and neuroprostanes (NeuroPs), derived from docosahexaenoic acid (DHA). We have shown increased levels of IsoPs, NeuroPs, and IsoFs in diseased regions of brain from patients who died from advanced Alzheimer's disease (AD) or Parkinson's disease (PD). Increased cerebrospinal fluid (CSF) levels of IsoPs are present in patients with AD or Huntington's disease (HD) early in the course of their illness, and CSF IsoPs may improve the laboratory diagnostic accuracy for AD. In contrast, quantification of IsoPs in plasma and urine of AD patients has yielded inconsistent results. These results indicate that brain lipid peroxidation is a potential therapeutic target early in the course of AD and HD, that CSF IsoPs may aid in the assessment of anti-oxidant experimental therapeutics and laboratory diagnosis of AD.

KW - Alzheimer

KW - Huntington

KW - Isofurans

KW - Isoprostanes

KW - Neuroprostanes

KW - Parkinson

UR - http://www.scopus.com/inward/record.url?scp=0842346368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0842346368&partnerID=8YFLogxK

U2 - 10.1016/j.chemphyslip.2003.10.010

DO - 10.1016/j.chemphyslip.2003.10.010

M3 - Review article

C2 - 15037157

AN - SCOPUS:0842346368

SN - 0009-3084

VL - 128

SP - 117

EP - 124

JO - Chemistry and Physics of Lipids

JF - Chemistry and Physics of Lipids

IS - 1-2

ER -

Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this